TY  - JOUR
A1  - Werner, Rudolf
A1  - Solnes, Lilja
A1  - Javadi, Mehrbod
A1  - Weich, Alexander
A1  - Gorin, Michael
A1  - Pienta, Kenneth
A1  - Higuchi, Takahiro
A1  - Buck, Andreas
A1  - Pomper, Martin
A1  - Rowe, Steven
A1  - Lapa, Constantin
T1  - SSTR-RADS Version 1.0 as a Reporting System for SSTR-PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework
JF  - Journal of Nuclear Medicine
N2  - Reliable standards and criteria for somatostatin receptor (SSTR) positron emission tomography (PET) are still lacking. We herein propose a structured reporting system on a 5-point scale for SSTR-PET imaging, titled SSTR-RADS version 1.0, which might serve as a standardized assessment for both diagnosis and treatment planning in neuroendocrine tumors (NET). SSTR-RADS could guide the imaging specialist in interpreting SSTR-PET scans, facilitate communication with the referring clinician so that appropriate work-up for equivocal findings is pursued, and serve as a reliable tool for patient selection for planned Peptide Receptor Radionuclide Therapy.
KW  - Radionuclide Therapy
KW  - Standardisierung
KW  - Positronen-Emissions-Tomografie
KW  - 68Ga-DOTATATE/-TOC
KW  - Gastrointestinal
KW  - Neuroendocrine
KW  - Neuroendocrine Tumor
KW  - Oncology
KW  - GI
KW  - PET
KW  - PET/CT
KW  - PRRT
KW  - RADS
KW  - SSTR
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-161298
SN  - 0161-5505
N1  - This  research  was  originally  published  in  JNM. Rudolf  A. Werner, Lilja  B. Solnes, Mehrbod Som  Javadi, Alexander  Weich, Michael A. Gorin, Kenneth J. Pienta, Takahiro  Higuchi, Andreas K. Buck, Martin G. Pomper, Steven P. Rowe, Constantin Lapa. SSTR-RADS Version 1.0 as   a Reporting System for SSTR-PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework. J. Nucl. Med. July 1, 2018, vol. 59, no. 7, 1085-1091. © SNMMI
ER  - 
TY  - JOUR
A1  - Werner, Rudolf A.
A1  - Weich, Alexander
A1  - Kircher, Malte
A1  - Solnes, Lilja B.
A1  - Javadi, Mehrbod S.
A1  - Higuchi, Takahiro
A1  - Buck, Andreas K.
A1  - Pomper, Martin G.
A1  - Rowe, Steven
A1  - Lapa, Constantin
T1  - The theranostic promise for neuroendocrine tumors in the late 2010s – Where do we stand, where do we go?
JF  - Theranostics
N2  - More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent years have expanded recommendations in current guidelines and included the evaluation of novel theranostic radiotracers for imaging and treatment of NET. Moreover, the introduction of standardized reporting framework systems may harmonize PET reading, address pitfalls in interpreting SSTR-PET/CT scans and guide the treating physician in selecting PRRT candidates. Notably, the concept of PRRT has also been applied beyond oncology, e.g. for treatment of inflammatory conditions like sarcoidosis. Future perspectives may include the efficacy evaluation of PRRT compared to other common treatment options for NET, novel strategies for closer monitoring of potential side effects, the introduction of novel radiotracers with beneficial pharmacodynamic and kinetic properties or the use of supervised machine learning approaches for outcome prediction. This article reviews how the SSTR-directed theranostic concept is currently applied and also reflects on recent developments that hold promise for the future of theranostics in this context.
KW  - theranostics
KW  - Positronen-Emissions-Tomografie
KW  - PRRT
KW  - somatostatin receptor
KW  - peptide receptor radionuclide therapy
KW  - neuroendocrine tumor
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-170264
VL  - 8
IS  - 22
ER  -